Oramed Pharmaceuticals
ORMP
24 hedge funds and large institutions have $850K invested in Oramed Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
14% more funds holding
Funds holding: 21 → 24 (+3)
1.05% more ownership
Funds ownership: 0% → 1.05% (+1.1%)
36% less capital invested
Capital invested by funds: $1.32M → $850K (-$471K)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $43K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$90.6K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$73.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$32.6K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$10.4K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$4.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$508K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$32.6K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$19K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.56K |
ORMP Hedge Fund Activity: Q4 2016 in Review
24 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2016, worth a combined $850K — down 36% from $1.32M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ORMP positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $90.6K. The largest seller was Tocqueville Asset Management, exiting entirely with an estimated $508K sold.
- 24 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2016, up from 21 in Q3 2016.
- Funds reported $850K of Oramed Pharmaceuticals stock for Q4 2016, down 36% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q4 2016 and 2 closed out, a net change of +3 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2016 was Virtu KCG Holdings, an estimated $90.6K added.
- The largest Oramed Pharmaceuticals seller in Q4 2016 was Tocqueville Asset Management, an estimated $508K sold.
Based on aggregated 13F filings for Q4 2016.